EFFECTS OF THE DRUG THIOGAMMA® ON THE SYMPTOMS OF PERIPHERAL DIABETIC POLYNEUROPATHY, AS WELL AS EVALUATION OF THE MENTAL STATUS IN PATIENTS WITH DIABETES MELLITUS AND OTHER DISORDERS OF CARBOHYDRATE METABOLISM
Keywords:
diabetes mellitus, diabetic polyneuropathy, MMSE scale, NIS-LL scale, alphalipoic (thioctic) acidAbstract
Loss of sensation in the feet and symptoms of muscle weakness are the main signs of peripheral diabetic polyneuropathy. The main problem of endocrinologists and other specialists in the field of diabetology is the difficulty of early diagnosis of the above complication of diabetes. In addition, the treatment of diabetic polyneuropathy is complicated by poor compensation, which may be associated with cognitive impairment in DM patients due to specific brain disorders. In our study, we assessed Mini-Mental State Examination (MMSE) mental status and Neuropathy Impairment Score — Low Limbs (NIS-LL) symptoms of muscle weakness and tenderness with Thiogamma® (Worwag Pharma) in 635 patients with diabetes and other disorders of carbohydrate metabolism.
References
Ametov AS, Barinov A., Dyck PJ et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26(3):770–6.
Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function.// J Clin Exp Neuropsychol. 26:1044-1080.
Cabezas-Cerra4. Christen W G., Manson JE, Bubes V, Glynn RJ // Am. J. epidemiol. - 1999. - Vol. 150. - P. 1142-1151
Effects of treatment with the antioxidant-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. (DECAN Study) // Diabetes Care.- 1997.-Vol.20,N.3.-P.369-373.
Esther SC Korf, Lon R. White, Ph Scheltens,et.al. Brain Aging in Very Old Men With Type 2 Diabetes The Honolulu-Asia Aging Study // Diabetes Care 29:2268-2274, 2006.
Gregg EW, Venkat Narayan KM.. Type 2 Diabetes and Cognitive Function: Are Cognitive Impairment and Dementia Complications of Type 2 Diabetes? // Clinical Geriatrics. Volume 08. P. 1070-1389.
Gries FA, Cameron NE, Low PA (eds.) Textbook of diabetic neuropathy. Stuttgart: Thieme, 2003
Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999; 31(3):171–9.
Van den Berg E, Kessels RP, Kappelle LJ, et. al. Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. // Drugs Today (Barc). 2006 ;Vol.42(11).P.741-54.
Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88(4):947–99.
Ziegler D., Ametov A., Barinov A. et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29(11):2365–70.
Ziegler D., Hanefeld M., Ruhnau RJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22(8):1296–301.
Ziegler D., Nowak H., Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med 2004;21(2):114–21.
Galstyan G.R., Antsiferov M.B. Treatment of distal diabetic polyneuropathy. // Russian Medical Journal. -2000.-N.4.-pp.201-203.to J. // Diabetologia. - 1998. - Vol. 41. - P. 1263-1269.
